Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Net Cash Flow (2018 - 2025)

Historic Net Cash Flow for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to -$71.9 million.

  • Bicycle Therapeutics' Net Cash Flow rose 44.32% to -$71.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$241.8 million, marking a year-over-year decrease of 17641.68%. This contributed to the annual value of $353.8 million for FY2024, which is 8973.08% up from last year.
  • As of Q3 2025, Bicycle Therapeutics' Net Cash Flow stood at -$71.9 million, which was up 44.32% from -$73.3 million recorded in Q2 2025.
  • Bicycle Therapeutics' 5-year Net Cash Flow high stood at $504.6 million for Q2 2024, and its period low was -$87.0 million during Q1 2025.
  • Moreover, its 5-year median value for Net Cash Flow was -$25.9 million (2022), whereas its average is $27.0 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first crashed by 120046.5% in 2022, then soared by 278058.88% in 2023.
  • Bicycle Therapeutics' Net Cash Flow (Quarter) stood at $179.2 million in 2021, then crashed by 114.44% to -$25.9 million in 2022, then plummeted by 81.5% to -$47.0 million in 2023, then surged by 79.64% to -$9.6 million in 2024, then tumbled by 651.77% to -$71.9 million in 2025.
  • Its Net Cash Flow stands at -$71.9 million for Q3 2025, versus -$73.3 million for Q2 2025 and -$87.0 million for Q1 2025.